Ceftazidime-avibactam versus ceftolozane-tazobactam in the treatment of drug-resistant Pseudomonas aeruginosa: a meta-analysis

医学 微生物学 假单胞菌 铜绿假单胞菌 抗生素 假单胞菌 假单胞菌感染 细菌 假单胞菌科 内科学
作者
Thamer A. Almangour,Sulaiman Alzunaydi,Felwah AlManea,Aisha Alshahwan,Shahd Mohammad,Leen Ghonem,Essam A. Tawfik,Mohammed AL Essa,Yazed Saleh Alsowaida
出处
期刊:International Journal of Infectious Diseases [Elsevier BV]
卷期号:165: 108485-108485 被引量:2
标识
DOI:10.1016/j.ijid.2026.108485
摘要

OBJECTIVES: Few studies comparing the clinical outcomes of the two novel agents ceftolozane-tazobactam (CT) and ceftazidime-avibactam (CA) in treating infections due to drug-resistant P. aeruginosa have been published. However, these studies demonstrated inconsistent findings and were limited by the small sample sizes. The aim of this meta-analysis is to evaluate the clinical outcomes of CA versus CT in treating infections caused by drug-resistant P. aeruginosa. METHODS: We conducted a comprehensive literature search up to March 2025 in Medline, Embase, Scopus, China National Knowledge Infrastructure, and Cochrane Library. Included studies should have examined the effectiveness of CA versus CT for the treatment of infections caused by resistant P. aeruginosa. Our primary outcome was 30-day mortality. We used the random-effects model, and our estimated effects were reported as odds ratios (ORs) with 95% confidence intervals. The study was registered in PROSPERO (CRD420251027545). RESULTS: A total of 10 studies and 1409 patients were included, 644 in CA group and 765 in CT group. When the data from 8 studies were pooled in a meta-analysis, 30-day mortality did not significantly differ in those who received CA compared to CT (OR = 0.93, 95% CI = 0.71-1.23, I-squared = 0.00%). No statistically significant differences were observed in the other outcomes. CONCLUSION: Our meta-analysis indicated that CA and CT demonstrated comparable clinical outcomes for the treatment of infection caused by resistant P. aeruginosa. However, limitations of the included studies should be acknowledged. More data are needed to validate these findings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田様的应助被酿酿也是酿酿采纳,获得10
1秒前
爆米花的应助被天道酬勤采纳,获得10
1秒前
xx发布了新的文献求助10
1秒前
hehe完成签到,获得积分20
1秒前
卡拉米完成签到,获得积分10
1秒前
fairy完成签到 ,获得积分20
2秒前
石宇航发布了新的文献求助10
3秒前
彭于晏的应助被kim采纳,获得30
4秒前
BOL发布了新的文献求助10
4秒前
1111完成签到,获得积分10
5秒前
6秒前
酒辞完成签到,获得积分10
6秒前
HSora完成签到,获得积分10
6秒前
6秒前
6秒前
18756828852发布了新的文献求助10
6秒前
7秒前
9秒前
积极的甜瓜完成签到,获得积分10
10秒前
10秒前
壹贰叁不伍完成签到,获得积分10
10秒前
田乐天完成签到 ,获得积分10
11秒前
zz完成签到 ,获得积分10
12秒前
林婉发布了新的文献求助10
12秒前
煎饼果子完成签到 ,获得积分10
13秒前
yexu完成签到,获得积分10
13秒前
Hello的应助被musk采纳,获得10
13秒前
14秒前
随风旅鼠发布了新的文献求助10
14秒前
yangz发布了新的文献求助10
15秒前
15秒前
踏实的荷花完成签到,获得积分10
16秒前
Luckystar发布了新的文献求助10
16秒前
17秒前
lin完成签到 ,获得积分10
17秒前
18秒前
18秒前
李健的小迷弟的应助被yangz采纳,获得10
18秒前
阿母死撞完成签到,获得积分10
19秒前
科研通AI65的应助被衡阳采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192078
求助须知:如何正确求助?哪些是违规求助? 9578670
关于积分的说明 21861341
捐赠科研通 7791469
什么是DOI,文献DOI怎么找? 3436771
关于科研通互助平台的介绍 2560538
邀请新用户注册赠送积分活动 2483557